Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) a biopharmaceutical company, is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 1.66 per share.
For the full year, analysts predict revenues of $ 469.94 million, while looking forward to loss of $ 6.46 per share.
Previous Quarter Performance
Alnylam Pharmaceuticals, Inc. posted loss for the second quarter of $ 1.67 per share, from the revenue of $ 103.96 million. The consensus estimates are loss of $ 1.74 per share from $ 99.48 million in revenue. The bottom line results beat street analysts by $ 0.07 or 4.02 percent, at the same time, top line results outshined analysts by $ 4.48 million or 4.50 percent.
Stock Performance
Shares of Alnylam Pharmaceuticals, Inc. traded up $ 10.44 or 8.09 percent on Wednesday, reaching $ 139.49 with volume of 874.10 thousand shares. Alnylam Pharmaceuticals, Inc. has traded high as $ 140.84 and has cracked $ 133.40 on the downward trend
The closing price of $ 139.49, representing a 51.88 % increase from the 52 week low of $ 84.97 and a 22.88 % decrease over the 52 week high of $ 167.33.
The company has a market capital of $ 16.18 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 15th October 2020, maintained by Bank of America at Buy rating, with $ 157.00 target price.
- On 8th September 2020, initiated by Citigroup at Buy rating, with $ 170.00 target price.
Conference Call
Alnylam Pharmaceuticals, Inc. will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.alnylam.com
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The companys pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
